U.S. Life Science Vacancy Hits 23.5% as Boston Lab Rents Drop Below $80
Updated
Updated · Area Development · May 20
U.S. Life Science Vacancy Hits 23.5% as Boston Lab Rents Drop Below $80
2 articles · Updated · Area Development · May 20
Roughly 200 million square feet of U.S. life science space is now on the market, with national vacancy at 23.5% after a 2021–2022 speculative building boom left major hubs oversupplied.
Boston, the Bay Area and San Diego hold about 130 million square feet of that inventory, and vacancy in those three markets has climbed above 30%; Boston also faces 3.5 million square feet of new supply not yet counted.
Recovery remains narrow: in 2025, just 8% of biotech funding rounds topped $100 million, yet they captured about 50% of venture dollars, while 60% of U.S. biotech VC flowed to Greater Boston and the Bay Area.
That capital concentration favors established, single-asset companies that need less space and shorter leases, while AI-driven drug discovery is starting to pull R&D footprints back toward a 50/50 office-lab split or lower.
Secondary markets such as Raleigh-Durham have absorbed more spec space after construction froze, but the broader outlook is a prolonged reset in which patent-cliff demand supports activity even as broad-based reshoring and a return to peak lab leasing look unlikely.
With AI poised to slash wet lab demand, how must overbuilt biotech hubs transform to survive?
Can AI-driven drug discovery thrive in the US despite federal funding cuts and an exodus of scientific talent?
As Chinese biotech rivals the US, where should investors place their bets in a resetting global market?
Boston’s Life Sciences Lab Market in 2026: Vacancy Rates, Funding Shifts, and Future Outlook
Overview
The U.S. life sciences real estate sector is in a period of rebalancing as of Q1 2026, with supply moderating and demand starting to firm up. Despite a 12% year-over-year decline in R&D property sales, investor interest is growing, highlighted by major deals like Healthpeak’s $600 million acquisition of Blackstone’s South San Francisco portfolio. These trends point toward a more sustainable phase for the market. With funding stabilizing and the industry well-positioned for a constructive year ahead, the sector is showing early signs of recovery and renewed momentum.